|
WO2020056459A1
|
|
Method of treating wasting disorders
|
|
WO2019218009A1
|
|
Soluble complement receptor type 1 variants and uses thereof
|
|
WO2019178645A1
|
|
Method of treating asthma
|
|
JP2019103502A
|
|
Il-11r binding proteins and uses thereof
|
|
BR112020011240A2
|
|
use of a fxiia inhibitor in the treatment of renal fibrosis and / or chronic kidney disease
|
|
CN111417406A
|
|
Methods of treating or preventing ischemia-reperfusion injury
|
|
CA3079014A1
|
|
Method
|
|
WO2019075519A1
|
|
Human serum albumin variants and uses thereof
|
|
WO2018132874A1
|
|
Method of preventing an immune response with alpha- 1 anti-trypsin
|
|
KR20190084095A
|
|
Reconstructed high-density lipoprotein therapy of myocardial infarction
|
|
EP3515948A1
|
|
Coagulation factor binding proteins and uses thereof
|
|
WO2017181243A1
|
|
Method of treating or preventing liver conditions
|
|
EP3440107A1
|
|
Method of treating atherosclerosis
|
|
BR112018010766A2
|
|
cd131-binding proteins and uses thereof
|
|
IL248101D0
|
|
Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor
|
|
AU2015258240A1
|
|
Method of improving the stability of purified factor viii after reconstitution
|
|
CN107106681A
|
|
The method for treating or preventing apoplexy
|
|
AU2015252110A1
|
|
Method of purifying polypeptides
|
|
KR20170040327A
|
|
Factor viii formulation
|
|
US2016024180A1
|
|
Purification of VWF
|
